Popular glucagon-like peptide-1 receptor agonists are associated with serious gastrointestinal adverse effects such as pancreatitis, gastroparesis and bowel obstruction, according to the results of a large retrospective study.
These agents “have potential serious side effects, and prescribers should be aware of them and feel comfortable managing adverse events [AEs] and understanding appropriate dosing strategies,” said Eduardo Grunvald, MD, the director of the weight management